300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Oil and Gas
Mobile
Film
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Software
Facebook
Blockchain
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
Cannabis
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
LGBT
Climate
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Poland
Puerto Rico
China
Guernsey
Cameroon
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Seychelles
Moldova
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Kenya
Latvia
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Angola
Europe
Bangladesh
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Belarus
Algeria
Finland
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Italy
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
GISEV Family Office, VC Fund

GISEV Family Office

VC Fund

Lugano, Switzerland

GISEV Family Office is a investment firm.

Total investments:
8
Last investment:
Lead investor:
25%

Last updated:

Industries GISEV Family Office invests in

Health CareBiotechnologyWellnessTherapeuticsPersonal Health

Stages GISEV Family Office invests in

Series ASeedPre-SeedSeries BSeries C

Countries GISEV Family Office invests in

United StatesArgentinaUnited Kingdom

Round sizes

Series A $11M–$40M

Round size

Series A
$11M–$40M

Investment Focus

Industry

  • Health Care 6 (75%)
  • Biotechnology 4 (50%)
  • Wellness 3 (38%)
  • Therapeutics 3 (38%)
  • Personal Health 2 (25%)
See all 14 industries →

Stage

  • Series A 3 (38%)
  • Seed 1 (13%)
  • Pre-Seed 1 (13%)
  • Series B 1 (13%)
  • Series C 1 (13%)
See all 6 stages →

Country

  • United States 6 (75%)
  • Argentina 1 (13%)
  • United Kingdom 1 (13%)

Investments

CompanyDescriptionRoundLinks
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. $43.2M / Series B / Nov 28, 2022
Revea is a us-based one-of-its-kind precision skincare company. $6M / Seed / Apr 21, 2022
Syocin Biotech is developing a synthetic biology platform for the redesign of natural existing biomolecules to precisely target plant bacterial pathogens that threaten world food availability. $450K / Pre-Seed / Dec 30, 2021
Seed Health is a microbial company that specializes in therapeutics, consumer health innovations, and environmental solutions. The company focuses on breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics. It was founded by Ara Katz and Raja Dhir in 2017 and is headquartered in Venice, California. $40M / Series A / Apr 21, 2021
Voy Voy
Manual is a men’s health and well-being startup offering a suite of diagnostic tools and blood tests to offer data-driven health solutions. The company provides men with easy access to advice, free medical support, and the treatment choices they need to help them make proactive decisions about their wellbeing.Manual was founded in 2018 and isheadquartered in London, UK. $30.2M / Series A / Mar 30, 2021
Solarea Bio is a biotech company that develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.It specializes in the research and development of therapeutics that are derived from natural sources and are aimed to treat indications derived from chronic inflammation, enabling hospitals toprovide medicinal drugs for improved quality of life. The company generates a large database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Its first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being.The Cambridge, Massachusetts-based company was established in 2017 by Eric Schott, Gerardo Toledo, and Jillian DeWalt. $11.2M / Series A / Oct 19, 2020
Symbiome offers skincare as nature intended solution which is scientifically and intentionally formulated using ancestral ingredients. It was founded in 2017 and is headquartered in San Francisco, California. $15M / Venture - Series Unknown / Sep 14, 2020
Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds.Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level. $40M / Series C / Dec 23, 2019

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Oil and Gas
Mobile
Film
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Software
Facebook
Blockchain
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
Cannabis
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
LGBT
Climate
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Poland
Puerto Rico
China
Guernsey
Cameroon
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Seychelles
Moldova
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Kenya
Latvia
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Angola
Europe
Bangladesh
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Belarus
Algeria
Finland
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Italy
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does GISEV Family Office invest in?

GISEV Family Office invests primarily in Health Care, Biotechnology and Wellness startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does GISEV Family Office invest in?

GISEV Family Office typically joins rounds of $11M–$40M at Series A. These are whole funding-round sizes, not GISEV Family Office's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds GISEV Family Office took part in.

When did GISEV Family Office last invest?

The most recent investment recorded for GISEV Family Office closed in Nov 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
GISEV Family Office GISEV Family Office Find emails